Piramal Enterprises’ CDMO to partner with BerGenBio

03 Dec 2019 Evaluate

Piramal Enterprises’ Contract Development and Manufacturing Organization (CDMO) -- Pharma Solutions business is all set to partner with BerGenBio ASA, on the development of bemcentinib for the treatment of elderly patients with relapsed Acute Myeloid Leukemia (AML).

Bemcentinib was designated as a Fast Track drug by the US Food and Drug Administration (FDA), as there are currently no marketed drugs specifically approved for relapsed AML patients, representing a significant unmet medical need.

Piramal Enterprises is one of India’s large diversified companies, with a presence in Pharmaceuticals, Healthcare Information Management and Financial Services.

Piramal Ent - Amalga Share Price

1124.60 0.00 (0.00%)
22-Sep-2025 16:59 View Price Chart
Peers
Company Name CMP
Bajaj Finance 950.50
Shriram Finance 995.55
Aditya Birla Capital 361.70
Chola Invest & Fin. 1699.45
Tata Capital 358.75
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×